208 related articles for article (PubMed ID: 6385258)
1. Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches.
Hamilton TC; Young RC; Ozols RF
Semin Oncol; 1984 Sep; 11(3):285-98. PubMed ID: 6385258
[No Abstract] [Full Text] [Related]
2. Pharmacologic reversal of drug resistance in ovarian cancer.
Ozols RF
Semin Oncol; 1985 Sep; 12(3 Suppl 4):7-11. PubMed ID: 4048979
[TBL] [Abstract][Full Text] [Related]
3. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
Caffrey PB; Zhang Y; Frenkel GD
Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
[TBL] [Abstract][Full Text] [Related]
4. Collateral susceptibility of adriamycin-, melphalan- and cisplatin-resistant human ovarian tumor cells to bleomycin.
Tsuruo T; Hamilton TC; Louie KG; Behrens BC; Young RC; Ozols RF
Jpn J Cancer Res; 1986 Sep; 77(9):941-5. PubMed ID: 2429947
[TBL] [Abstract][Full Text] [Related]
5. Cell survival in four ovarian carcinoma xenografts following in vitro exposure to melphalan, cisplatin and cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA,JM8).
Jones AC; Wilson PA; Steel GG
Cancer Chemother Pharmacol; 1984; 13(2):109-13. PubMed ID: 6380788
[TBL] [Abstract][Full Text] [Related]
6. Treatment of human ovarian tumor xenografts with selenite prevents the melphalan-induced development of drug resistance.
Caffrey PB; Frenkel GD
Anticancer Res; 1998; 18(4C):3017-20. PubMed ID: 9713502
[TBL] [Abstract][Full Text] [Related]
7. Biological aspects of the subrenal capsule assay of importance in the screening of cytostatic agents.
Edelstein MB; Smink T; van Putten LM
Behring Inst Mitt; 1984 May; (74):285-90. PubMed ID: 6477357
[No Abstract] [Full Text] [Related]
8. Effect of five antineoplastic agents on tumor xenografts with different growth rates.
Mattern J; Wayss K; Volm M
J Natl Cancer Inst; 1984 Jun; 72(6):1335-9. PubMed ID: 6587154
[TBL] [Abstract][Full Text] [Related]
9. Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts.
Taetle R; Rosen F; Abramson I; Venditti J; Howell S
Cancer Treat Rep; 1987 Mar; 71(3):297-304. PubMed ID: 3815395
[TBL] [Abstract][Full Text] [Related]
10. Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines.
Harstrick A; Schmoll HJ; Sass G; Poliwoda H; Rustum Y
Eur J Cancer; 1993; 29A(7):1000-2. PubMed ID: 8499130
[TBL] [Abstract][Full Text] [Related]
11. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
[TBL] [Abstract][Full Text] [Related]
12. Modulation of drug resistance in human ovarian cancer: experimental results and clinical applications.
Ozols RF; Hamilton TC; Young RC
Prog Clin Biol Res; 1986; 223():173-85. PubMed ID: 3809199
[No Abstract] [Full Text] [Related]
13. Circumvention of cisplatin resistance in ovarian cancer by combination of cyclosporin A and low-intensity ultrasound.
Yu T; Yang Y; Zhang J; He H; Ren X
Eur J Pharm Biopharm; 2015 Apr; 91():103-10. PubMed ID: 25668779
[TBL] [Abstract][Full Text] [Related]
14. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3.
Ma L; Lai D; Liu T; Cheng W; Guo L
Acta Biochim Biophys Sin (Shanghai); 2010 Sep; 42(9):593-602. PubMed ID: 20705681
[TBL] [Abstract][Full Text] [Related]
15. [Primary study of arsenic trioxide inhibits abdomino-metastatic tumor formation of human ovarian carcinoma in nude mice and its mechanisms].
Huang SG; Kong BH; Yang RF; Jiang S
Ai Zheng; 2002 Apr; 21(4):401-4. PubMed ID: 12452020
[TBL] [Abstract][Full Text] [Related]
16. Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence.
Frei E; Ara G; Teicher B; Bunnell C; Richardson P; Wheeler C; Tew K; Elias A
Cancer Chemother Pharmacol; 2000; 45(3):239-46. PubMed ID: 10663642
[TBL] [Abstract][Full Text] [Related]
17. Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts.
Kolfschoten GM; Hulscher TM; Pinedo HM; Boven E
Br J Cancer; 2000 Oct; 83(7):921-7. PubMed ID: 10970695
[TBL] [Abstract][Full Text] [Related]
18. Time- and dose-dependence of DNA fragmentation induced by anticancer agents: a flow cytometric study.
Cappella P; Onado C; Sena G; Montalenti F; Spinelli L; Ubezio P
Eur J Histochem; 1997; 41 Suppl 2():67-8. PubMed ID: 9859787
[No Abstract] [Full Text] [Related]
19. [Chemotherapy of ovarian cancer based on in vitro (HTCA) and in vivo (nude mice) chemosensitivity testing].
Sagawa T; Yamashita K; Kawamura M; Shimizu T; Haga H; Yorozu Y; Kasamo M; Fujita M
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Jul; 37(7):1197-204. PubMed ID: 2411831
[TBL] [Abstract][Full Text] [Related]
20. [New approaches in experimental cancerology: in search of therapeutic models].
Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Pierré A; Hickman J
Bull Cancer; 2001 Jan; 88(1):75-84. PubMed ID: 11182656
[No Abstract] [Full Text] [Related]
[Next] [New Search]
